The VC Home Bias Problem: Why European Investors Refuse to Cross the Street
Venture capital, in theory, is about finding the best startups, wherever they may be. In practice? Many European VCs barely
The Corporate Award Industrial Complex: A Trophy for Everyone
There are few things as vague yet self-important as the phrase “award-winning”. It’s a flex, a flourish, a signal
The Boutique Consultancy Mirage
Few phrases carry as much self-importance and ambiguity as “boutique consultancy”. It appears on websites, LinkedIn bios, and PowerPoint decks
The Conference Conundrum: Pay-to-Play, Ego Panels, and Networking Woes
Let’s talk about a topic that doesn’t get enough attention but is painfully familiar to anyone in the
The problem with LOA
Likelihood of Approval (LOA) is a widely referenced metric in drug development, particularly in the later stages of the pipeline.
The problem with PTRS
Probability of Technical and Regulatory Success (PTRS) is a widely used metric in biotech and pharma, employed to estimate the
Assessing the Robustness of Biotech Valuations Using Fat-Tailed Models
Biotech valuations, characterized by their high volatility and dependency on uncertain outcomes, present unique challenges to traditional financial modeling. The
The Project Management Paradox: Why Big Pharma Execs Struggle in the Real World
Project management—the noble art of being handed a budget, a timeline, and a goal, then tasked with delivering results
Why Incorporating Fat Tails, Black Swans, and Extreme Value Theory (EVT) Can Improve Pitch Decks
Fat Tails, Black Swans, and Extreme Value Theory (EVT) offer a robust analytical framework for understanding rare, high-impact events that
WhatsApp: From Skeptic to Believer—How It’s Building Communities
When I first considered WhatsApp as a professional communication channel, I was deeply skeptical. It felt too informal, too personal.
